Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 12.12 -0.63 (-4.90%)
As of 12:23 PM Eastern
Compare

CREO vs. EKF, IUG, IHC, NCYT, and RUA

Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), Novacyt (NCYT), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.

How does Creo Medical Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

EKF Diagnostics has a beta of 0.491, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 1.498894, suggesting that its share price is 50% more volatile than the S&P 500.

22.4% of EKF Diagnostics shares are held by institutional investors. Comparatively, 45.2% of Creo Medical Group shares are held by institutional investors. 39.7% of EKF Diagnostics shares are held by company insiders. Comparatively, 4.1% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.17£4.68M£0.4755.11
Creo Medical Group£4.60M10.87-£25.04M-£1.00N/A

Creo Medical Group has a net margin of 768.18% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 32.72% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 768.18%32.72%-20.09%

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 35.14%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than Creo Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. EKF Diagnostics' average media sentiment score of 0.67 beat Creo Medical Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Positive
Creo Medical Group Neutral

Summary

EKF Diagnostics beats Creo Medical Group on 11 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Creo Medical Group (LON:CREO) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Creo Medical Group has a net margin of 768.18% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 32.72% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group768.18% 32.72% -20.09%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
Creo Medical Group Neutral
Intelligent Ultrasound Group Neutral

45.2% of Creo Medical Group shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 4.1% of Creo Medical Group shares are owned by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Intelligent Ultrasound Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£4.60M10.87-£25.04M-£1.00N/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

Creo Medical Group has a beta of 1.498894, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Intelligent Ultrasound Group beats Creo Medical Group on 6 of the 10 factors compared between the two stocks.

How does Creo Medical Group compare to Inspiration Healthcare Group?

Creo Medical Group (LON:CREO) and Inspiration Healthcare Group (LON:IHC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Creo Medical Group has a net margin of 768.18% compared to Inspiration Healthcare Group's net margin of -25.32%. Creo Medical Group's return on equity of 32.72% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group768.18% 32.72% -20.09%
Inspiration Healthcare Group -25.32%-69.35%-3.47%

Creo Medical Group has a beta of 1.498894, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Inspiration Healthcare Group has a beta of 0.717, meaning that its stock price is 28% less volatile than the S&P 500.

45.2% of Creo Medical Group shares are owned by institutional investors. Comparatively, 10.2% of Inspiration Healthcare Group shares are owned by institutional investors. 4.1% of Creo Medical Group shares are owned by insiders. Comparatively, 8.4% of Inspiration Healthcare Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Inspiration Healthcare Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Inspiration Healthcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£4.60M10.87-£25.04M-£1.00N/A
Inspiration Healthcare Group£45.20M0.63-£12.20M-£13.65N/A

In the previous week, Inspiration Healthcare Group had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for Inspiration Healthcare Group and 0 mentions for Creo Medical Group. Inspiration Healthcare Group's average media sentiment score of 0.67 beat Creo Medical Group's score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
Inspiration Healthcare Group Positive

Summary

Inspiration Healthcare Group beats Creo Medical Group on 7 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to Novacyt?

Novacyt (LON:NCYT) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Creo Medical Group has a net margin of 768.18% compared to Novacyt's net margin of -125.04%. Creo Medical Group's return on equity of 32.72% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-125.04% -62.56% -27.98%
Creo Medical Group 768.18%32.72%-20.09%

Creo Medical Group has lower revenue, but higher earnings than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£19.45M1.10-£36.80M-£43.00N/A
Creo Medical Group£4.60M10.87-£25.04M-£1.00N/A

Novacyt has a beta of 0.973, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 1.498894, suggesting that its stock price is 50% more volatile than the S&P 500.

10.7% of Novacyt shares are held by institutional investors. Comparatively, 45.2% of Creo Medical Group shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 4.1% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Novacyt had 2 more articles in the media than Creo Medical Group. MarketBeat recorded 2 mentions for Novacyt and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.00 beat Novacyt's score of -0.23 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
Novacyt Neutral
Creo Medical Group Neutral

Summary

Creo Medical Group beats Novacyt on 10 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to RUA Life Sciences?

RUA Life Sciences (LON:RUA) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 45.2% of Creo Medical Group shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by insiders. Comparatively, 4.1% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

RUA Life Sciences has a beta of 0.632, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 1.498894, indicating that its share price is 50% more volatile than the S&P 500.

RUA Life Sciences has higher earnings, but lower revenue than Creo Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.02-£2.66MN/AN/A
Creo Medical Group£4.60M10.87-£25.04M-£1.00N/A

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Creo Medical Group Neutral

Creo Medical Group has a net margin of 768.18% compared to RUA Life Sciences' net margin of -3.26%. Creo Medical Group's return on equity of 32.72% beat RUA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Creo Medical Group 768.18%32.72%-20.09%

Summary

Creo Medical Group beats RUA Life Sciences on 6 of the 10 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£50.01M£2.16B£6.28B£2.79B
Dividend YieldN/A2.62%2.77%6.11%
P/E Ratio-12.1313.7429.35365.56
Price / Sales10.87128.44492.0688,050.39
Price / Cash2.4315.9943.4227.89
Price / Book0.935.189.847.52
Net Income-£25.04M£144.75M£3.55B£5.89B
7 Day Performance-1.02%1.82%3.90%8.64%
1 Month Performance12.79%4.14%6.04%6.24%
1 Year Performance18.29%8.28%40.49%89.04%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 12.13
-4.9%		N/A+18.1%£50.01M£4.60MN/A279
EKF
EKF Diagnostics
2.6806 of 5 stars		GBX 26.71
+0.0%		GBX 35
+31.0%		+22.9%£115.14M£51.56M56.83356
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 29.60
+0.7%		N/A+75.9%£26.54M£45.20MN/A224
NCYT
Novacyt
N/AGBX 26.60
-10.0%		N/A-25.9%£19.28M£19.45MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel